In the medium and long term there is no clear superiority of one treatment over another. Pain during therapeutic exercise for chronic musculoskeletal pain need not be a barrier to successful outcomes.

In Moldova, the Treatment of Musculoskeletal Diseases market is expected to generate a revenue of US$13.68m by the year 2024. It is projected to experience a steady annual growth rate (CAGR 2024 ...

Musculoskeletal disorders currently afflict approximately 1.71 billion individuals globally, representing a major public health and economic challenge, ...

Increasing Opportunity for Manufacturers to Develop Customised Shock Wave Therapy Devices Tailored to Specific Medical ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

This article discusses musculoskeletal pain, its potential causes, and treatment options. Musculoskeletal pain is typically localized to the body part affected by an injury or disease. In addition ...

MSK Doctors (03300010048), a London-based private practice that specialises in treatments for musculoskeletal disorders, has released a new ...

Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.

The Department for Work and Pensions (DWP) has launched a new scheme to fast-track treatment for people with musculoskeletal (MSK) conditions, such as issues with backs, joints, and muscles ...

The DWP has announced that a new fund will be set up to help people with back pain, joint issues and muscle ailments to get ...

The Department for Work and Pensions (DWP) has launched a new scheme to fast-track treatment for people with musculoskeletal (MSK) conditions, targeting areas with the longest waiting times.